Cargando…

A bioavailable cathepsin S nitrile inhibitor abrogates tumor development

BACKGROUND: Cathepsin S has been implicated in a variety of malignancies with genetic ablation studies demonstrating a key role in tumor invasion and neo-angiogenesis. Thus, the application of cathepsin S inhibitors may have clinical utility in the treatment of cancer. In this investigation, we appl...

Descripción completa

Detalles Bibliográficos
Autores principales: Wilkinson, Richard D. A., Young, Andrew, Burden, Roberta E., Williams, Rich, Scott, Christopher J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839156/
https://www.ncbi.nlm.nih.gov/pubmed/27097645
http://dx.doi.org/10.1186/s12943-016-0513-7
_version_ 1782428104240660480
author Wilkinson, Richard D. A.
Young, Andrew
Burden, Roberta E.
Williams, Rich
Scott, Christopher J.
author_facet Wilkinson, Richard D. A.
Young, Andrew
Burden, Roberta E.
Williams, Rich
Scott, Christopher J.
author_sort Wilkinson, Richard D. A.
collection PubMed
description BACKGROUND: Cathepsin S has been implicated in a variety of malignancies with genetic ablation studies demonstrating a key role in tumor invasion and neo-angiogenesis. Thus, the application of cathepsin S inhibitors may have clinical utility in the treatment of cancer. In this investigation, we applied a cell-permeable dipeptidyl nitrile inhibitor of cathepsin S, originally developed to target cathepsin S in inflammatory diseases, in both in vitro and in vivo tumor models. METHODS: Validation of cathepsin S selectivity was carried out by assaying fluorogenic substrate turnover using recombinant cathepsin protease. Complete kinetic analysis was carried out and true K(i) values calculated. Abrogation of tumour invasion using murine MC38 and human MCF7 cell lines were carried out in vitro using a transwell migration assay. Effect on endothelial tube formation was evaluated using primary HUVEC cells. The effect of inhibitor in vivo on MC38 and MCF7 tumor progression was evaluated using cells propagated in C57BL/6 and BALB/c mice respectively. Subsequent immunohistochemical staining of proliferation (Ki67) and apoptosis (TUNEL) was carried out on MCF7 tumors. RESULTS: We confirmed that this inhibitor was able to selectively target cathepsin S over family members K, V, L and B. The inhibitor also significantly reduced MC38 and MCF7 cell invasion and furthermore, significantly reduced HUVEC endothelial tubule formation in vitro. In vivo analysis revealed that the compound could significantly reduce tumor volume in murine MC38 syngeneic and MCF7 xenograft models. Immunohistochemical analysis of MCF7 tumors revealed cathepsin S inhibitor treatment significantly reduced proliferation and increased apoptosis. CONCLUSIONS: In summary, these results highlight the characterisation of this nitrile cathepsin S inhibitor using in vitro and in vivo tumor models, presenting a compound which may be used to further dissect the role of cathepsin S in cancer progression and may hold therapeutic potential. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-016-0513-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4839156
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-48391562016-04-22 A bioavailable cathepsin S nitrile inhibitor abrogates tumor development Wilkinson, Richard D. A. Young, Andrew Burden, Roberta E. Williams, Rich Scott, Christopher J. Mol Cancer Research BACKGROUND: Cathepsin S has been implicated in a variety of malignancies with genetic ablation studies demonstrating a key role in tumor invasion and neo-angiogenesis. Thus, the application of cathepsin S inhibitors may have clinical utility in the treatment of cancer. In this investigation, we applied a cell-permeable dipeptidyl nitrile inhibitor of cathepsin S, originally developed to target cathepsin S in inflammatory diseases, in both in vitro and in vivo tumor models. METHODS: Validation of cathepsin S selectivity was carried out by assaying fluorogenic substrate turnover using recombinant cathepsin protease. Complete kinetic analysis was carried out and true K(i) values calculated. Abrogation of tumour invasion using murine MC38 and human MCF7 cell lines were carried out in vitro using a transwell migration assay. Effect on endothelial tube formation was evaluated using primary HUVEC cells. The effect of inhibitor in vivo on MC38 and MCF7 tumor progression was evaluated using cells propagated in C57BL/6 and BALB/c mice respectively. Subsequent immunohistochemical staining of proliferation (Ki67) and apoptosis (TUNEL) was carried out on MCF7 tumors. RESULTS: We confirmed that this inhibitor was able to selectively target cathepsin S over family members K, V, L and B. The inhibitor also significantly reduced MC38 and MCF7 cell invasion and furthermore, significantly reduced HUVEC endothelial tubule formation in vitro. In vivo analysis revealed that the compound could significantly reduce tumor volume in murine MC38 syngeneic and MCF7 xenograft models. Immunohistochemical analysis of MCF7 tumors revealed cathepsin S inhibitor treatment significantly reduced proliferation and increased apoptosis. CONCLUSIONS: In summary, these results highlight the characterisation of this nitrile cathepsin S inhibitor using in vitro and in vivo tumor models, presenting a compound which may be used to further dissect the role of cathepsin S in cancer progression and may hold therapeutic potential. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-016-0513-7) contains supplementary material, which is available to authorized users. BioMed Central 2016-04-21 /pmc/articles/PMC4839156/ /pubmed/27097645 http://dx.doi.org/10.1186/s12943-016-0513-7 Text en © Wilkinson et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Wilkinson, Richard D. A.
Young, Andrew
Burden, Roberta E.
Williams, Rich
Scott, Christopher J.
A bioavailable cathepsin S nitrile inhibitor abrogates tumor development
title A bioavailable cathepsin S nitrile inhibitor abrogates tumor development
title_full A bioavailable cathepsin S nitrile inhibitor abrogates tumor development
title_fullStr A bioavailable cathepsin S nitrile inhibitor abrogates tumor development
title_full_unstemmed A bioavailable cathepsin S nitrile inhibitor abrogates tumor development
title_short A bioavailable cathepsin S nitrile inhibitor abrogates tumor development
title_sort bioavailable cathepsin s nitrile inhibitor abrogates tumor development
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4839156/
https://www.ncbi.nlm.nih.gov/pubmed/27097645
http://dx.doi.org/10.1186/s12943-016-0513-7
work_keys_str_mv AT wilkinsonrichardda abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment
AT youngandrew abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment
AT burdenrobertae abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment
AT williamsrich abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment
AT scottchristopherj abioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment
AT wilkinsonrichardda bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment
AT youngandrew bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment
AT burdenrobertae bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment
AT williamsrich bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment
AT scottchristopherj bioavailablecathepsinsnitrileinhibitorabrogatestumordevelopment